<DOC>
	<DOC>NCT00395460</DOC>
	<brief_summary>The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.</brief_summary>
	<brief_title>Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<criteria>Chinese origin, with known or suspected brain or spine diseases Pregnancy Lactation Conditions interfering with MRI Allergy to any contrast agent or any drugs Participation in other trial Require emergency treatment Severely impaired liver and kidney functions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Gadovist</keyword>
	<keyword>Gadavist</keyword>
	<keyword>Contrast agent</keyword>
	<keyword>Brain</keyword>
	<keyword>Spine disease</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
</DOC>